Each year we dedicate on average 20% of our revenue to product development as well as projects that increase the efficiency of our manufacturing operations. By maintaining a high commitment to R&D, we are able to fuel the continuous development of new technologies and satisfy the clinical and economic needs of our customers.
As a result of our commitment to innovation, we have a portfolio of over 650 medical devices and a pipeline filled with the next generation of breakthrough technologies for minimally invasive surgery. Our advanced technologies enable General, Cardiac, Vascular, Urologic, Bariatric, Gynecologic, Obstetric, and Colorectal surgeons to provide their patients with enhanced clinical outcomes.
